Ascidian Therapeutics is a biotechnology company that offers an RNA therapeutics platform to treat genetic diseases. The platform replaces mutated exons that cause disease and performs large-scale DNA and RNA synthesis, enabling patients to access treatment without the risks of direct DNA editing or gene replacement while maintaining endogenous gene expression circuitry. Ascidian's therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. The company has active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, opening new therapeutic possibilities for patients in need of breakthroughs.